These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
231 related articles for article (PubMed ID: 32760143)
1. Development of an adjuvanted nanoparticle vaccine against influenza virus, an in vitro study. Rungrojcharoenkit K; Sunintaboon P; Ellison D; Macareo L; Midoeng P; Chaisuwirat P; Fernandez S; Ubol S PLoS One; 2020; 15(8):e0237218. PubMed ID: 32760143 [TBL] [Abstract][Full Text] [Related]
2. Broadly protective immunity against divergent influenza viruses by oral co-administration of Lactococcus lactis expressing nucleoprotein adjuvanted with cholera toxin B subunit in mice. Lei H; Peng X; Jiao H; Zhao D; Ouyang J Microb Cell Fact; 2015 Aug; 14():111. PubMed ID: 26242406 [TBL] [Abstract][Full Text] [Related]
3. Nasal vaccination with r4M2e.HSP70c antigen encapsulated into N-trimethyl chitosan (TMC) nanoparticulate systems: Preparation and immunogenicity in a mouse model. Dabaghian M; Latifi AM; Tebianian M; NajmiNejad H; Ebrahimi SM Vaccine; 2018 May; 36(20):2886-2895. PubMed ID: 29627234 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of the immunogenicity and protective effects of a trivalent chimeric norovirus P particle immunogen displaying influenza HA2 from subtypes H1, H3 and B. Gong X; Yin H; Shi Y; He X; Yu Y; Guan S; Kuai Z; Haji NM; Haji NM; Kong W; Shan Y Emerg Microbes Infect; 2016 May; 5(5):e51. PubMed ID: 27222326 [TBL] [Abstract][Full Text] [Related]
5. An approach to the influenza chimeric subunit vaccine (3M2e-HA2-NP) provides efficient protection against lethal virus challenge. Saleh M; Nowroozi J; Farahmand B; Fotouhi F Biotechnol Lett; 2020 Jul; 42(7):1147-1159. PubMed ID: 32152828 [TBL] [Abstract][Full Text] [Related]
6. Immunity and Protective Efficacy of Mannose Conjugated Chitosan-Based Influenza Nanovaccine in Maternal Antibody Positive Pigs. Renu S; Feliciano-Ruiz N; Patil V; Schrock J; Han Y; Ramesh A; Dhakal S; Hanson J; Krakowka S; Renukaradhya GJ Front Immunol; 2021; 12():584299. PubMed ID: 33746943 [TBL] [Abstract][Full Text] [Related]
11. Targeting the HA2 subunit of influenza A virus hemagglutinin via CD40L provides universal protection against diverse subtypes. Fan X; Hashem AM; Chen Z; Li C; Doyle T; Zhang Y; Yi Y; Farnsworth A; Xu K; Li Z; He R; Li X; Wang J Mucosal Immunol; 2015 Jan; 8(1):211-20. PubMed ID: 25052763 [TBL] [Abstract][Full Text] [Related]
12. Combination of M2e peptide with stalk HA epitopes of influenza A virus enhances protective properties of recombinant vaccine. Tsybalova LM; Stepanova LA; Shuklina MA; Mardanova ES; Kotlyarov RY; Potapchuk MV; Petrov SA; Blokhina EA; Ravin NV PLoS One; 2018; 13(8):e0201429. PubMed ID: 30138320 [TBL] [Abstract][Full Text] [Related]
13. Cross-protection against influenza virus infection by intranasal administration of nucleoprotein-based vaccine with compound 48/80 adjuvant. Zheng M; Liu F; Shen Y; Wang S; Xu W; Fang F; Sun B; Xie Z; Chen Z Hum Vaccin Immunother; 2015; 11(2):397-406. PubMed ID: 25607884 [TBL] [Abstract][Full Text] [Related]
14. Mucosal vaccination of conserved sM2, HA2 and cholera toxin subunit A1 (CTA1) fusion protein with poly gamma-glutamate/chitosan nanoparticles (PC NPs) induces protection against divergent influenza subtypes. Chowdhury MYE; Kim TH; Uddin MB; Kim JH; Hewawaduge CY; Ferdowshi Z; Sung MH; Kim CJ; Lee JS Vet Microbiol; 2017 Mar; 201():240-251. PubMed ID: 28284616 [TBL] [Abstract][Full Text] [Related]
15. [Increasing the immunogenicity of inactivated chitosan adjuvanted vaccine from A/California/7/09 (H1N1) strain and analyzing the antigenic specificity of this influenza virus strain]. Gendon IuZ; Markushin SG; Vasil'ev IuM; Akopova II; Krivtsov GG Vopr Virusol; 2012; 57(1):28-33. PubMed ID: 22624470 [TBL] [Abstract][Full Text] [Related]
17. Mucosal immunization with recombinant influenza hemagglutinin protein and poly gamma-glutamate/chitosan nanoparticles induces protection against highly pathogenic influenza A virus. Moon HJ; Lee JS; Talactac MR; Chowdhury MY; Kim JH; Park ME; Choi YK; Sung MH; Kim CJ Vet Microbiol; 2012 Dec; 160(3-4):277-89. PubMed ID: 22763171 [TBL] [Abstract][Full Text] [Related]
18. Responses of primary human nasal epithelial cells to COVID-19 vaccine candidate. Jakaew P; Jearanaiwitayakul T; Midoeng P; Masrinoul P; Sunintaboon P; Ubol S Asian Pac J Allergy Immunol; 2024 Jan; ():. PubMed ID: 38183648 [TBL] [Abstract][Full Text] [Related]
19. The highly conserved HA2 protein of the influenza A virus induces a cross protective immune response. Lee JS; Chowdhury MY; Moon HJ; Choi YK; Talactac MR; Kim JH; Park ME; Son HY; Shin KS; Kim CJ J Virol Methods; 2013 Dec; 194(1-2):280-8. PubMed ID: 24004822 [TBL] [Abstract][Full Text] [Related]
20. Unmasking Stem-Specific Neutralizing Epitopes by Abolishing N-Linked Glycosylation Sites of Influenza Virus Hemagglutinin Proteins for Vaccine Design. Liu WC; Jan JT; Huang YJ; Chen TH; Wu SC J Virol; 2016 Oct; 90(19):8496-508. PubMed ID: 27440889 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]